Staying informed about the ever-evolving landscape of public health is critical, both domestically and globally. Recent reports highlight significant challenges facing local health departments in the United States, alongside updates on global infectious disease threats like mpox and avian flu. Meanwhile, key decisions regarding vaccine policy are unfolding at federal agencies, underscoring the complex interplay between science, policy, and public well-being. This summary breaks down the most vital public health news impacting communities today.
Workforce Strains & Budget Woes Hit Local Health Departments
Local public health departments form the backbone of America’s defense against health threats, yet they are facing increasing pressure. A new report from the National Association of County and City Health Officials (NACCHO) paints a concerning picture of a shrinking public health safety net. The 2024 Forces of Change Survey, which gathered insights from over 660 local health departments across the US, reveals rising rates of job losses and budget cuts.
Alarming Trends in Staffing and Funding
According to the survey, 19% of local health departments reported job losses in 2023 due to layoffs or staff leaving. This rate has steadily climbed from 14% in 2021 and 17% in 2022. For large health departments, the situation is even more critical, with nearly 40% experiencing workforce reductions. Financial strain is also evident, as 17% of departments reported budget cuts in fiscal year 2024, and a higher percentage, 23%, anticipate further cuts in fiscal year 2025. These trends raise serious questions about the capacity of local agencies to provide essential services.
The survey also shed light on the multifaceted roles of public health nurses, finding 90% are involved in health promotion and protection efforts. A significant 72% contribute to emergency preparedness and disaster recovery work. Furthermore, 41% of nurses are engaged in policy and advocacy, demonstrating their broad impact. Despite efforts to evaluate program effectiveness, nearly 60% of departments cited insufficient staff time as a major challenge to conducting evaluations. Compounding these issues, few local health departments are hosting individuals from training or fellowship programs, a factor that NACCHO warns puts future workforce development at risk. The latest findings underscore critical trends and challenges faced by local health departments during this period of uncertainty.
Tracking Emerging Threats Through Wastewater Monitoring
In a proactive move to bolster disease surveillance, NACCHO, with support from the Centers for Disease Control and Prevention (CDC), is investing in innovative tools. NACCHO recently announced awarding $356,000 to support local health departments in implementing and expanding wastewater monitoring programs. Now in its fourth year, the Wastewater Monitoring Mentorship Program connects experienced departments with those just starting.
Expanding Surveillance Capacity
The program selected five local health departments as mentors and eleven as mentees for the 2025 cycle. Notably, this year’s program emphasized including rural health departments to address the unique barriers they may face in conducting wastewater analysis. Wastewater monitoring has proven to be a valuable tool for detecting viruses and other pathogens circulating within a community, often providing early warnings of potential outbreaks before clinical cases are widely reported.
Mentor health departments receiving awards are located in California, Massachusetts, Nebraska, and Texas. Mentees are spread across several states, including Alaska, California, Iowa, Ohio, Missouri, Texas, and West Virginia. The initiative aims to equip more communities with the tools needed to effectively track infectious disease trends and respond rapidly to emerging health threats.
Global Health Threats: Mpox and Avian Flu Updates
Beyond national borders, public health officials are closely monitoring several infectious disease outbreaks. Updates from Africa on mpox and new human cases of H5N1 avian flu in Cambodia highlight ongoing vigilance required on a global scale.
Mpox Progress in Africa Amid Funding Challenges
According to Dr. Yap Boum, deputy incident manager for Africa CDC’s mpox response, there’s an encouraging trend in Africa’s mpox outbreaks. Sierra Leone, which had become a significant hotspot, has seen a decline in cases over the past six weeks. This success is partly attributed to increased involvement of community healthcare workers and the effective pairing of contact tracing with vaccination efforts. While Sierra Leone shows improvement, Uganda has reported a slight rise in cases recently, likely due to enhanced contact tracing finding more infections. Over the past week, Uganda, Sierra Leone, and Zambia accounted for a large majority (88%) of confirmed mpox cases in Africa.
Despite the positive trends in controlling outbreaks, a critical challenge remains: vaccine funding. While Bavarian Nordic mpox vaccine supply is available, organizations like UNICEF reportedly lack the funds to purchase doses for allocation to African countries. Dr. Boum described this funding gap as a significant challenge, a crisis, and an imperative of equity, emphasizing the need for resources to capitalize on current progress and ensure affected populations have access to protection.
New Human H5N1 Avian Flu Case in Cambodia
Cambodia’s health ministry has confirmed another human case of H5N1 avian flu, the 12th case reported so far this year. The latest case involves a 5-year-old boy from Kampot province who is currently in intensive care. This follows a concerning uptick in human cases in Cambodia since late 2023, with a recent acceleration, including nine cases reported since early June.
Investigations into the boy’s case revealed his family owned a flock of 40 chickens, some of which were sick or had died. The boy reportedly played with the chickens daily, highlighting the typical route of transmission through close contact with infected poultry. H5N1 is known to circulate widely in Cambodian poultry populations. Experts have identified a new reassortant virus circulating that contains genetic material from both an older Cambodian H5N1 strain and the globally circulating 2.3.4.4b clade. Human infections with either strain are often severe or fatal, making each new case a serious concern for public health officials monitoring the virus’s activity.
US Federal Agencies and Vaccine Policy Decisions
Decisions made by federal health agencies like the CDC and FDA have widespread implications for public health strategies and individual vaccination choices. Recent events involving vaccine recommendations and approvals have drawn significant attention.
CDC Accepts April ACIP Vaccine Recommendations
The US CDC has accepted three vaccine recommendations made by its Advisory Committee on Immunization Practices (ACIP) during their April meeting. These recommendations were formally adopted by Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. on June 25.
The accepted recommendations include:
Allowing the use of GSK’s new pentavalent meningococcal vaccine when both quadrivalent and monovalent B meningococcal vaccines are indicated simultaneously.
Recommending a single dose of RSV vaccine for adults aged 50 to 59 years who are considered at risk for severe RSV disease. The CDC plans to issue further clinical considerations detailing these risk factors.
Providing guidance for chikungunya vaccines, recommending Bavarian Nordic’s vaccine for travelers to outbreak areas, those moving to high-risk countries, and potentially exposed lab workers, and Valneva’s chikungunya vaccine for travelers to outbreak locations and individuals spending extended time in higher-risk settings.
This acceptance signals official guidance for healthcare providers regarding the use of these vaccines in specific populations.
Report: FDA Official Overruled Scientists on COVID Vaccine Approvals
Separately, a report in The New York Times indicates that Dr. Vinay Prasad, who leads the FDA’s Center for Biologics Evaluation and Research, reportedly overruled the recommendations of the agency’s own scientists regarding the broad approval of two newer COVID-19 vaccines.
According to the report, FDA scientists, following extensive review, had recommended full approval for Novavax’s protein-based COVID vaccine for anyone aged 12 and older. However, in mid-May, the FDA announced approval specifically limited to individuals aged 65 and older and younger people with underlying health conditions. Similarly, FDA scientists evaluated Moderna’s mNexspike vaccine and found it slightly more effective than the original version with a comparable safety profile, recommending its use for anyone aged 12 and older. Despite this, in early June, the FDA approved this vaccine only for use in people aged 65 and older and younger individuals with health conditions increasing their risk for COVID complications. This reported discrepancy between scientific recommendations and final regulatory decisions has raised questions within the scientific and public health communities.
Brief Global & National Updates
Beyond these major points, other health alerts have emerged:
The Pan American Health Organization (PAHO) has assessed yellow fever risk in the Americas as high, noting an eightfold increase in human cases this year compared to last, with detection spreading outside traditional Amazon regions.
China reported a human case of H5N1 avian flu in a recovered woman, suspected to be imported from Vietnam.
Moderna has submitted its updated COVID vaccine, targeting the LP.8.1 sublineage of JN.1, for FDA review, aligning with recent guidance on vaccine composition.
- Measles activity continues, with New Mexico reporting the virus in a wastewater sample, Utah reporting cases in unvaccinated adults, and significant activity noted across the Americas.
- www.cidrap.umn.edu
- www.cidrap.umn.edu
- www.cidrap.umn.edu
- www.cidrap.umn.edu
- www.cidrap.umn.edu
Frequently Asked Questions
What key issues are impacting local health departments in the US?
Local health departments are facing significant challenges, primarily concerning workforce capacity and funding. Recent survey data shows increasing job losses (19% in 2023, nearly 40% in large departments) and budget cuts (17% in FY2024, 23% anticipated in FY2025). These strains make it difficult to maintain essential services and conduct important work like program evaluation, where insufficient staff time is a major barrier. The lack of training program participants also raises concerns for the future public health workforce.
How are public health agencies working to track emerging health threats?
Public health agencies are increasingly utilizing tools like wastewater monitoring to track disease trends and identify emerging threats. The NACCHO Wastewater Monitoring Mentorship Program, supported by the CDC, awards funding to local health departments to implement and expand these surveillance systems. By analyzing wastewater, departments can detect viruses and other pathogens circulating in a community, often providing early warnings of potential outbreaks before they are widely reported through clinical data. The program also focuses on supporting rural areas with this technology.
Why is there a reported shortage of mpox vaccine funding in Africa?
According to Africa CDC officials, despite the availability of Bavarian Nordic mpox vaccine supply for purchase, there is a shortage of funds for procurement by organizations like UNICEF that allocate doses to countries. This funding gap poses a significant challenge for African nations making progress in controlling outbreaks and seeing good vaccine uptake. The lack of funding prevents the necessary purchase and distribution of vaccines, potentially hindering control efforts and raising issues of equity in access to essential public health tools during a critical phase of the response.
Conclusion
These recent updates underscore the dynamic nature of public health. From the persistent challenges facing local infrastructure and workforce in the United States to the ongoing battle against global infectious diseases like mpox and H5N1, and critical decisions shaping vaccine availability, staying informed is paramount. The reports highlight the need for sustained investment in public health capacity, continued vigilance against emerging threats, and transparent processes in vaccine policy to protect communities worldwide.
